HR 7352119th CongressIn Committee
PASTEUR Act of 2026
Standard Summary
Balanced plain-English summary
The PASTEUR Act of 2026 amends the Public Health Service Act to create a subscription-style contract program that incentivizes development of innovative antimicrobial drugs targeting serious and urgent resistant pathogens. It establishes scoring criteria, advisory group oversight, annual payments, stewardship grants, surveillance requirements, and $6 billion in appropriated funding.
Key Points
- 1Creates U.S. Novel Antimicrobial Supply Contracts with annual payments ranging from $75 million to $300 million.
- 2Establishes a Critical Need Antimicrobial Advisory Group and a scoring system for eligible antimicrobial drugs.
- 3Funds hospital and outpatient antimicrobial stewardship programs and expands surveillance of resistance and use.
- 4Appropriates $6 billion for fiscal year 2026 to carry out the program.
Impact Areas
Patients with drug-resistant infectionsHospitals and health care facilitiesAntimicrobial drug developers and manufacturersPublic health surveillance systemsFederal health agencies and Medicare/Medicaid programs
Generated by deepseek/deepseek-v4.1-flash-1017Nov 18, 2026